Abstract
Adenosine is a ubiquitous signaling molecule, with widespread activity across all organ systems. There is evidence that adenosine regulation is a significant factor in traumatic brain injury (TBI) onset, recovery, and outcome, and a growing body of experimental work examining the therapeutic potential of adenosine neuromodulation in the treatment of TBI. In the central nervous system (CNS), adenosine (dys)regulation has been demonstrated following TBI, and correlated to several TBI pathologies, including impaired cerebral hemodynamics, anaerobic metabolism, and inflammation. In addition to acute pathologies, adenosine function has been implicated in TBI comorbidities, such as cognitive deficits, psychiatric function, and post-traumatic epilepsy. This review presents studies in TBI as well as adenosine-related mechanisms in co-morbidities of and unfavorable outcomes resulting from TBI. While the exact role of the adenosine system following TBI remains unclear, there is increasing evidence that a thorough understanding of adenosine signaling will be critical to the development of diagnostic and therapeutic tools for the treatment of TBI.
Keywords: Adenosine deaminase, adenosine kinase, nucleotidase, nucleoside transport, caffeine, comorbidity
Current Neuropharmacology
Title: Adenosine Neuromodulation and Traumatic Brain Injury
Volume: 7 Issue: 3
Author(s): T. A. Lusardi
Affiliation:
Keywords: Adenosine deaminase, adenosine kinase, nucleotidase, nucleoside transport, caffeine, comorbidity
Abstract: Adenosine is a ubiquitous signaling molecule, with widespread activity across all organ systems. There is evidence that adenosine regulation is a significant factor in traumatic brain injury (TBI) onset, recovery, and outcome, and a growing body of experimental work examining the therapeutic potential of adenosine neuromodulation in the treatment of TBI. In the central nervous system (CNS), adenosine (dys)regulation has been demonstrated following TBI, and correlated to several TBI pathologies, including impaired cerebral hemodynamics, anaerobic metabolism, and inflammation. In addition to acute pathologies, adenosine function has been implicated in TBI comorbidities, such as cognitive deficits, psychiatric function, and post-traumatic epilepsy. This review presents studies in TBI as well as adenosine-related mechanisms in co-morbidities of and unfavorable outcomes resulting from TBI. While the exact role of the adenosine system following TBI remains unclear, there is increasing evidence that a thorough understanding of adenosine signaling will be critical to the development of diagnostic and therapeutic tools for the treatment of TBI.
Export Options
About this article
Cite this article as:
Lusardi A. T., Adenosine Neuromodulation and Traumatic Brain Injury, Current Neuropharmacology 2009; 7 (3) . https://dx.doi.org/10.2174/157015909789152137
DOI https://dx.doi.org/10.2174/157015909789152137 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Towards Drug Discovery for Brain Tumours: Interaction of Kinins and Tumours at the Blood Brain Barrier Interface
Recent Patents on CNS Drug Discovery (Discontinued) Beneficial Extracardiac Effects of Cardiovascular Medications
Current Cardiology Reviews Gene Therapy Approaches for Neuroprotection and Axonal Regeneration after Spinal Cord and Spinal Root Injury
Current Gene Therapy Current Pharmaceutical Design on Adhesive Based Transdermal Drug Delivery Systems
Current Pharmaceutical Design Preclinical Models of Graves’ Disease and Associated Secondary Complications
Current Pharmaceutical Design Alkaloids Pharmacological Activities - Prospects for the Development of Phytopharmaceuticals for Neurodegenerative Diseases
Current Pharmaceutical Biotechnology NO Chimeras as Therapeutic Agents in Alzheimers Disease
Current Alzheimer Research The Monoaminergic Tripartite Synapse: A Putative Target for Currently Available Antidepressant Drugs
Current Drug Targets Atheroprotective Properties of Pigment Epithelium-Derived Factor (PEDF) in Cardiometabolic Disorders
Current Pharmaceutical Design Therapeutic Targets in Prostaglandin E2 Signaling for Neurologic Disease
Current Medicinal Chemistry Competitive Gly/NMDA Receptor Antagonists
Current Topics in Medicinal Chemistry Efficacy of PD-1 or PD-L1 Inhibitors and Central Nervous System Metastases in Advanced Cancer: A Meta-Analysis
Current Cancer Drug Targets An Update of the Review of Neuropsychological Consequences of HIV and Substance Abuse: A Literature Review and Implications for Treatment and Future Research
Current Drug Abuse Reviews MicroRNAs: The New Challenge for Traumatic Brain Injury Diagnosis
Current Neuropharmacology Adverse Effects and Drug Interactions of Biologic Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Use of the Adamantane Structure in Medicinal Chemistry
Current Medicinal Chemistry Carbonic Anhydrase Inhibitors as Anticonvulsant Agents
Current Topics in Medicinal Chemistry Early Prediction of Preeclampsia: Hope for Early Intervention?
Current Women`s Health Reviews Platelet-neutrophil Interactions as a Target for Prevention and Treatment of Transfusion- related Acute Lung Injury
Current Pharmaceutical Design Astragaloside IV Supplementation Promotes A Neuroprotective Effect in Experimental Models of Neurological Disorders: A Systematic Review
Current Neuropharmacology